Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 12/20 | 0.55 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510792 | 0.92 | PRKAA2 (0.50) | PRKAA2EPHX2TEAD1 | |
| SCHEMBL12226758 | 0.92 | PRKAA2 (0.43) | PRKAA2CYP3A4EPHX2ARTEAD1 | |
| SCHEMBL12199813 | 0.91 | PRKAA2 (0.55) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL2503938 | 0.88 | PRKAA2 (0.50) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL17722960 | 0.85 | SLC6A5 (0.46) | PRKAA2ARTEAD1 | |
| SCHEMBL2507541 | 0.85 | SCN9A (0.44) | PRKAA2CETPEPHX2ARTEAD1 | |
| Hydrochloric Acid SCHEMBL1081664 | 0.84 | SCN9A (0.43) | PRKAA2CETPEPHX2ARTEAD1 | |
| SCHEMBL2504574 | 0.84 | HDAC4 (0.46) | PRKAA2 | |
| SCHEMBL2507265 | 0.84 | AR (0.39) | PRKAA2CETPEPHX2ARTEAD1 | |
| SCHEMBL2507192 | 0.83 | CETP (0.41) | PRKAA2CYP3A4CETPEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106928211-B | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-09-08 | — | — | CN | claimed |
| US-8785449-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | claimed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| CN-112079769-A | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-106928211-B | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | PRKAA2 413/4885PRKAB2 541/4885PRKAG1 860/4885 |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | PRKAA2 3/4885PRKAB2 8/4885PRKAG1 6/4885 |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | PC, AK2, PRKAA2 | PRKAA2 3/4885PRKAB2 8/4885PRKAG1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.